Skip to main content Skip to main content
Go to homepage

Nexium in Pediatric Patients with Erosive Esophagitis

Safety and Efficacy of Nexium in Pediatric Patients with Erosive Esophagitis


The purpose of this study is to look at the use of Nexium in helping to heal Erosive Esophagitis (EE), which is irritation in the pipe that carries food from your mouth to your stomach. This study will look at children aged 1-11 years old.

Who May Qualify?:


  • Age 1-11 years old
  • With at least a 3-month history of GERD
  • With confirmed presence of EE at time of endoscopy
  • Weighing greater than or equal to 10 kg (22 lbs)
Who Does Not Qualify:


  • Requiring surgery during the study period
  • With a significant clinical illness within 4 weeks prior to the start of treatment
  • With a hypersensitivity to Nexium or any other PPI
  • Less than 1 or greater than 11 years old
Interested in participating?
We are currently recruiting
Study Sponsor:


Full IRB Study Title:
A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years of Age
IRB Study ID:
If you are interested in this study or have questions about your child's eligibility, please contact:

Merry Tomcany,, 330-543-4616

Lead Investigator
Kevin Watson, MD, FAAP

Pediatric Gastroenterologist; Assistant Director, Clinical Informatics, Specialty Systems; Medical Director, Therapy Plans
Pediatric Gastroenterology

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.